Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435

Clinical and Experimental Metastasis

Volumn 23, Issue 2, 2006, Pages 123-133

  Shevde, Lalita A ^a,b,c   Samant, Rajeev S ^a,b,c   Paik, Jason C ^b   Metge, Brandon J ^a   Chambers, Ann F ^d   Casey, Graham ^e   Frost, Andra R ^b,c   Welch, Danny R ^b,c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d LONDON REGIONAL CANCER PROGRAM   (Canada)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Invasion; Migration; Osteopontin; RNA interference; Tumorigenicity

Indexed keywords

GLYCOPROTEIN; INITIATION FACTOR 2ALPHA; OSTEOPONTIN; SHORT HAIRPIN RNA;

ARTICLE; BREAST CARCINOMA; CARCINOGENICITY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL STRAIN; CELL STRAIN MDA MB 435; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OSTEOPONTIN; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748963245     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9013-2     Document Type: Article

References (49)

1. Singhal H, Bautista DS, Tonkin KS et al. (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3(4):605-611
2. Tuck AB, O'Malley FP, Singhal H et al. (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79(5):502-508
3. Agrawal D, Chen T, Irby R et al. (2002) Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. J Natl Cancer Inst 94(7):513-521
4. Rudland PS, Platt-Higgins A, El-Tanani M et al. (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427
5. Coppola D, Szabo M, Boulware D et al. (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184-190
6. Tuck AB, Arsenault DM, O'Malley FP et al. (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18(29):4237-4236
7. Oates AJ, Barraclough R, Rudland PS (1996) The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13(1):97-104
8. Philip S, Bulbule A, Kundu G (2001) Osteopontin promotes tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276(48):44926-44935
9. Adwan H, Bauerle TJ, Berger MR (2004) Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11(2):109-120
10. Adwan H, Bauerle T, Najajreh Y et al. (2004) Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 24(5):1235-1234
11. Tani-Ishii N, Tsunoda A, Umemoto T (1997) Osteopontin antisense deoxyoligonucleotides inhibit bone resorption by mouse osteoclasts in vitro. J Periodontal Res 32(6):480-486
12. Mukhopadhyay R, Price JE (1999) Stable expression of antisense osteopontin inhibits the growth of human breast cancer cells. Proc Am Assoc Cancer Res, 90th Annual Meeting, Philadelphia, PA, April 10-14, 40:448
13. Gardner HA, Berse B, Senger DR (1994) Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9(8):2321-2326
14. Su L, Mukherjee AB, Mukherjee BB (1995) Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene 10(11):2163-2169
15. Behrend EI, Craig AM, Wilson SM et al. (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54(3):832-837
16. Nemoto H, Rittling SR, Yoshitake H et al. (2001) Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16(4):652-659
17. Wu Y, Denhardt DT, Rittling SR (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83(2):156-163
18. Rittling SR, Novick KE (1997) Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ 8(10):1061-1069
19. Furger KA, Menon RK, Tuck AB et al. (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621-632
20. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6(4):419-429
21. Rittling SR, Chambers AF (2004) Role of osteopontin in tumor progression. BR J Cancer 90:1877-1881
22. Cook AC, Tuck AB, McCarthy S et al. (2005) Osteopontin induces multiple changes in gene expression that reflect the six "Hallmarks of Cancer" in a model of breast cancer progression. Mol Carcinogenesis 43:225-236
23. Khodavirdi AC, Song Z, Yang S et al. (2006) Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66(2):883-888
24. McManus M, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Revs 3:737-747
25. Medema RH (2004) Optimizing RNA interference for application in mammalian cells. Biochem J 380(Pt 3):593-603
26. Santner SJ, Dawson PD, Tait L et al. (2001) Malignant MCF10CA1 celllines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65:101-110
27. Miller FR, Santner SJ, Tait L et al. (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92(14):1185-1186
28. Price JE, Polyzos A, Zhang RD et al. (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 51:717-721
29. Ellison G, Klinowska T, Westwood RF et al. (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55(5):294-299
30. Ross DT, Scherf U, Eisen MB et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227-235
31. Sellappan S, Grijalva R, Zhou X et al. (2004) Lineage infedility of MDA-MB-435 cells. Cancer Res 64:3479-3485
32. Bautista DS, Xuan JW, Hota C et al. (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269(37):23280-23285
33. Christensen B, Nielsen MS, Haselmann KF et al. (2005) Post-translationally modified residues of native osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285-292
34. Kon S, Maeda M, Segawa T et al. (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77:487-498
35. Editorial (2003) Whither RNAi?. Nat Cell Biol 5(6):489-490
36. Sledz CA, Holko M, de Veer MJ et al. (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5(9):834-839
37. Naumov GN, MacDonald IC, Weinmeister PM et al. (2002) Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 62(7):2162-2168
38. Shevde LA, Samant RS, Goldberg SF et al. (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 273(2):229-239
39. Piyathilake CJ, Frost AR, Manne U et al. (2002) Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8(3):734-744
40. Chang PL, Chambers AF (2000) Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin. J Cell Biochem 78(1):8-23
41. Furger KA, Allan AL, Wilson SM et al. (2003) Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1(11):810-819
42. Noti JD (2000) Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 17(6):1237-1243
43. Takahashi F, Akutagawa S, Fukumoto H et al. (2002) Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98(5):707-712
44. Hirama M, Takahashi F, Takahashi K et al. (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198(1):107-117
45. Jessen KA, Liu SY, Tepper CG et al. (2004) Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 6(3):R157-R169
46. Mi Z, Guo H, Wai PY et al. (2004) Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 279(45):46659-46667
47. Teramoto H, Castellone MD, Malek RL et al. (2004) Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. Nov 01; doi:10.1038/sj.onc.1208209
48. Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 121(2):228-241
49. Khan SA, Lopez-Chua CA, Zhang J et al. (2002) Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Biol Chem 85(4):728-736